Madison Amos
Physician Assistant · Greenbrae
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Greenbrae Dermatology, A Medical Corporation · 6 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Madison Amos’s office at (415) 925-0550 to ask if they take your plan before you enroll.
California Medical Board record
Licence A62769 · Cancelled
Licence status: Cancelled · since 1997 · Indiana University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Colorado PA.5175Physician assistant · since 2017 · expires 2022-01-31ExpiredNo board action on this licenceCheck it with the stateWhat they told the state about themselves
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$78,712
Medicare paid this office $78,712 for 297 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 184 | $15,226 | $74 |
| Destruction of skin growth, 1-14 growths | 125 | $13,490 | $98 |
| Biopsy of related skin growth, first growth | 85 | $6,197 | $70 |
| Return visit (30+ min) | 51 | $5,715 | $99 |
| Destruction of precancer skin growth, 1 growth | 129 | $5,425 | $38 |
See all 11 services
| Short return visit (20+ min) | 184 | $15,226 | $74 |
| Destruction of skin growth, 1-14 growths | 125 | $13,490 | $98 |
| Biopsy of related skin growth, first growth | 85 | $6,197 | $70 |
| Return visit (30+ min) | 51 | $5,715 | $99 |
| Destruction of precancer skin growth, 1 growth | 129 | $5,425 | $38 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 17 | $4,473 | $248 |
| New patient visit (30+ min) | 44 | $3,408 | $77 |
| Destruction of precancer skin growth, 2-14 growths | 84 | $2,835 | $6 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,471 | $105 |
| Biopsy of related skin growth, each additional growth | 16 | $913 | $43 |
| Short return visit | 13 | $612 | $47 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 35 | More than 82% of doctors who do this |
| Removal of skin lesions | 699 | More than 90% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 258 | More than 88% of doctors who do this |
Who their Medicare patients are
297 Original Medicare patients in 2024. Average age 76 · Women 62% · Also on Medicaid 5% · Health risk score 0.93. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 53% · Coronary heart disease 18% · Cancer 18% · Atrial fibrillation 18% · Depression 15% · Chronic kidney disease 13% · Diabetes 9% · COPD 8% · Heart failure 6% · Stroke 6% · Dementia 5%.
The office billed $239,695, Medicare allowed $101,296 and paid $78,712; for 1,389 services of 37 kinds; $11,597 of it was for drugs given in the office and $67,114 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 297 | 1,389 | 76 | 0.93 | $239,695 | $78,712 |
| 2023 | 146 | 482 | 75 | 1.13 | $104,110 | $21,497 |
| 2022 | 233 | 925 | 75 | 0.95 | $189,572 | $44,297 |
| 2021 | 218 | 706 | 74 | 0.99 | $116,789 | $37,765 |
| 2020 | 109 | 301 | 70 | 1.09 | $46,226 | $14,651 |
| 2019 | 68 | 240 | 70 | 0.95 | $37,592 | $13,420 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Destruction of skin growth, 1-14 growths | 46 | $3,472 | $71 |
| Biopsy of related skin growth, first growth | 46 | $2,876 | $63 |
| Short return visit (20+ min) | 52 | $2,808 | $49 |
| Destruction of precancer skin growth, 1 growth | 45 | $1,798 | $32 |
| New patient visit (30+ min) | 24 | $1,505 | $63 |
| Short return visit | 20 | $891 | $42 |
| New patient visit (15+ min) | 14 | $836 | $60 |
| Biopsy of related skin growth, each additional growth | 16 | $751 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $552 | $5 |
| Return visit (30+ min) | 12 | $521 | $43 |
2022: 10 services
| Short return visit (20+ min) | 124 | $8,197 | $56 |
| Destruction of skin growth, 1-14 growths | 61 | $5,739 | $77 |
| Return visit (30+ min) | 30 | $3,483 | $87 |
| Biopsy of related skin growth, first growth | 69 | $3,481 | $48 |
| Destruction of precancer skin growth, 1 growth | 68 | $2,372 | $29 |
| New patient visit (30+ min) | 36 | $2,020 | $56 |
| Application of ultraviolet light to skin | 15 | $1,335 | $17 |
| Short return visit | 24 | $987 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 47 | $844 | $5 |
| Biopsy of related skin growth, each additional growth | 18 | $806 | $32 |
2021: 9 services
| Short return visit (20+ min) | 128 | $9,918 | $64 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 16 | $6,377 | $92 |
| Biopsy of related skin growth, first growth | 67 | $4,791 | $68 |
| New patient visit (30+ min) | 43 | $3,273 | $76 |
| Destruction of skin growth, 1-14 growths | 27 | $2,655 | $83 |
| Biopsy of related skin growth, each additional growth | 26 | $1,723 | $40 |
| Destruction of precancer skin growth, 1 growth | 41 | $1,685 | $34 |
| Return visit (30+ min) | 14 | $1,404 | $88 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $499 | $5 |
2020: 9 services
| Biopsy of related skin growth, first growth | 25 | $1,442 | $53 |
| Destruction of skin growth, 1-14 growths | 19 | $1,215 | $61 |
| Short return visit (20+ min) | 19 | $1,031 | $49 |
| Short return visit | 37 | $974 | $25 |
| New patient visit (15+ min) | 20 | $867 | $43 |
| Destruction of precancer skin growth, 1 growth | 22 | $852 | $34 |
| Return visit (30+ min) | 11 | $754 | $69 |
| New patient visit (30+ min) | 14 | $676 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 15 | $222 | $4 |
2019: 8 services
| Destruction of skin growth, 1-14 growths | 19 | $1,494 | $68 |
| Biopsy of related skin growth, first growth | 22 | $1,330 | $53 |
| Short return visit | 26 | $1,080 | $30 |
| Short return visit (20+ min) | 16 | $862 | $51 |
| New patient visit (30+ min) | 13 | $814 | $63 |
| New patient visit (15+ min) | 15 | $685 | $46 |
| Destruction of precancer skin growth, 1 growth | 17 | $582 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 12 | $125 | $4 |
Drugs they prescribed that Part D paid
$42,053
Pharmacies billed $42,053 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 298) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
284 generic and 14 brand-name prescriptions · $42,053 in drug cost · 14 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 28 | $2,012 | $72 |
| Ketoconazole | 55 | $961 | $17 |
| Mupirocin | 34 | $328 | $10 |
| Doxycycline Hyclate | 21 | $324 | $15 |
| Triamcinolone Acetonide | 48 | $305 | $6 |
See all 7 drugs
| Clobetasol Propionate | 28 | $2,012 | $72 |
| Ketoconazole | 55 | $961 | $17 |
| Mupirocin | 34 | $328 | $10 |
| Doxycycline Hyclate | 21 | $324 | $15 |
| Triamcinolone Acetonide | 48 | $305 | $6 |
| Nystatin | 17 | $230 | $14 |
| Hydrocortisone | 19 | $75 | $4 |
Year by year
| 2024 | 298 | 156 | 0% (0) | 5% | $42,053 |
| 2023 | 246 | 110 | 0% (0) | 9% | $60,286 |
| 2022 | 389 | 171 | 0% (0) | 7% | $27,719 |
| 2021 | 304 | 166 | 0% (0) | 9% | $41,430 |
| 2020 | 175 | 90 | 0% (0) | 21% | $47,036 |
| 2019 | 237 | 124 | 0% (0) | 19% | $74,129 |
| 2018 | 128 | 80 | None | None | $17,556 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Dupixent | 13 | $50,606 | $3,893 |
| Ketoconazole | 60 | $1,313 | $22 |
| Triamcinolone Acetonide | 62 | $758 | $12 |
| Mupirocin | 16 | $141 | $9 |
2022: 8 drugs
| Ketoconazole | 83 | $2,080 | $25 |
| Clobetasol Propionate | 17 | $1,403 | $83 |
| Betamethasone Dipropionate | 14 | $1,162 | $83 |
| Triamcinolone Acetonide | 74 | $746 | $10 |
| Doxycycline Hyclate | 17 | $665 | $39 |
| Nystatin | 16 | $540 | $34 |
| Mupirocin | 16 | $157 | $10 |
| Hydrocortisone | 14 | $76 | $5 |
2021: 8 drugs
| Clobetasol Propionate | 37 | $1,833 | $50 |
| Betamethasone Dipropionate | 23 | $1,285 | $56 |
| Ketoconazole | 44 | $1,090 | $25 |
| Betamethasone Diprop Augmented | 17 | $935 | $55 |
| Doxycycline Hyclate | 20 | $563 | $28 |
| Triamcinolone Acetonide | 42 | $326 | $8 |
| Hydrocortisone | 23 | $210 | $9 |
| Mupirocin | 14 | $116 | $8 |
2020: 4 drugs
| Clobetasol Propionate | 38 | $2,642 | $70 |
| Betamethasone Valerate | 11 | $432 | $39 |
| Mupirocin | 17 | $232 | $14 |
| Triamcinolone Acetonide | 14 | $86 | $6 |
2019: 7 drugs
| Clobetasol Propionate | 15 | $2,049 | $137 |
| Betamethasone Dipropionate | 23 | $1,934 | $84 |
| Fluocinolone Acetonide | 12 | $660 | $55 |
| Betamethasone Valerate | 14 | $524 | $37 |
| Mupirocin | 19 | $163 | $9 |
| Cephalexin | 18 | $130 | $7 |
| Triamcinolone Acetonide | 19 | $111 | $6 |
2018: 2 drugs
| Gentamicin Sulfate | 14 | $614 | $44 |
| Cephalexin | 22 | $131 | $6 |
Money from drug and device companies
$1,004 in 2025
| 2025 | 15 | 39 | None | $1,004 |
| 2024 | 10 | 25 | None | $833 |
| 2023 | 15 | 25 | None | $652 |
| 2022 | 17 | 94 | None | $1,714 |
| 2021 | 12 | 45 | None | $781 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Incyte | Opzelura | $138 | 6 payments
|
| Arcutis Biotherapeutics | Zoryve | $115 | 6 payments
|
| Regeneron Healthcare Solutions | Dupixent | $113 | 3 payments
|
| Abbvie | Rinvoq | $87 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $84 | 3 payments
|
| Merz North America | None | $75 | 2 payments
|
See all 39 published payments
| Organon | Meals · 2025-12-17 | None | $11 |
| Amgen | Meals · 2025-12-04 | Otezla | $27 |
| Regeneron Healthcare Solutions | Meals · 2025-11-20 | Libtayo | $39 |
| LEO Pharma | Meals · 2025-11-17 | Anzupgo | $20 |
| Abbvie | Meals · 2025-11-07 | Rinvoq | $19 |
| Arcutis Biotherapeutics | Meals · 2025-11-06 | Zoryve | $14 |
| Arcutis Biotherapeutics | Meals · 2025-10-24 | Zoryve | $16 |
| LEO Pharma | Meals · 2025-10-14 | Anzupgo | $16 |
| Novartis Pharmaceuticals | Meals · 2025-10-13 | Cosentyx | $24 |
| Pfizer | Meals · 2025-10-06 | Cibinqo | $23 |
| Pfizer | Meals · 2025-09-26 | Cibinqo | $25 |
| Sun Pharmaceutical Industries | Meals · 2025-09-22 | Ilumya | $26 |
| Organon | Meals · 2025-09-18 | None | $31 |
| Organon | Meals · 2025-09-12 | None | $13 |
| Arcutis Biotherapeutics | Meals · 2025-09-08 | Zoryve | $24 |
| Abbvie | Meals · 2025-08-29 | Rinvoq | $35 |
| LEO Pharma | Meals · 2025-08-26 | Adbry | $26 |
| Genzyme | Meals · 2025-08-21 | Dupixent | $39 |
| Merz North America | Meals · 2025-08-20 | None | $28 |
| Galderma Laboratories L.P. | Meals · 2025-08-12 | Nemluvio | $26 |
| Incyte | Meals · 2025-07-19 | Opzelura | $27 |
| Arcutis Biotherapeutics | Meals · 2025-07-15 | Zoryve | $18 |
| Incyte | Meals · 2025-06-18 | Opzelura | $26 |
| Incyte | Meals · 2025-05-28 | Opzelura | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-06 | Cosentyx | $30 |
| Incyte | Meals · 2025-04-11 | Opzelura | $25 |
| Arcutis Biotherapeutics | Meals · 2025-04-08 | Zoryve | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-03-25 | Dupixent | $36 |
| Biofrontera | Meals · 2025-03-17 | None | $33 |
| Pfizer | Meals · 2025-03-11 | Cibinqo | $17 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Dupixent | $37 |
| Amgen | Meals · 2025-02-14 | None | $32 |
| Merz North America | Meals · 2025-02-12 | None | $48 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Cosentyx | $30 |
| Incyte | Meals · 2025-02-04 | Opzelura | $28 |
| Incyte | Meals · 2025-02-03 | Opzelura | $2 |
| Lilly USA | Meals · 2025-01-23 | Taltz | $29 |
| Abbvie | Meals · 2025-01-21 | Skyrizi | $33 |
| Arcutis Biotherapeutics | Meals · 2025-01-14 | Zoryve | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $833
| Sun Pharmaceutical Industries | Ilumya | $138 | 3 payments
|
| Galderma Laboratories L.P. | None | $135 | 2 payments
|
| Amgen | Otezla | $109 | 4 payments
|
| Ucb | Bimzelx | $105 | 4 payments
|
| Merz North America | Xeomin | $105 | 3 payments
|
| Abbvie | Skyrizi | $78 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $59 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $57 | 2 payments
|
| Incyte | Opzelura | $28 | 1 payment
|
| Genzyme | Dupixent | $18 | 1 payment
|
2023: $652
| Sun Pharmaceutical Industries | Ilumya | $123 | 1 payment
|
| Janssen Biotech | Tremfya | $81 | 3 payments
|
| Abbvie | Skyrizi | $64 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $60 | 3 payments
|
| Almirall | Seysara | $47 | 2 payments
|
| Genzyme | Dupixent | $42 | 2 payments
|
| LEO Pharma | Adbry | $40 | 2 payments
|
| Amgen | Otezla | $39 | 2 payments
|
| Lilly USA | Taltz | $33 | 1 payment
|
| Arcutis Biotherapeutics | None | $24 | 1 payment
|
| Dermavant Sciences | Vtama | $22 | 1 payment
|
| Galderma Laboratories L.P. | None | $20 | 1 payment
|
| Incyte | Opzelura | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $19 | 1 payment
|
| Pfizer | Eucrisa | $17 | 1 payment
|
2022: $1,714
| Abbvie | Skyrizi | $262 | 13 payments
|
| Incyte | Opzelura | $255 | 21 payments
|
| Regeneron Healthcare Solutions | Dupixent | $249 | 11 payments
|
| Genzyme | Dupixent | $193 | 9 payments
|
| Sun Pharmaceutical Industries | Ilumya | $132 | 7 payments
|
| Almirall | Klisyri | $120 | 6 payments
|
| Lilly USA | Taltz | $111 | 5 payments
|
| Janssen Biotech | Remicade | $91 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $72 | 5 payments
|
| LEO Pharma | Adbry | $52 | 3 payments
|
| Amgen | Otezla | $37 | 2 payments
|
| Galderma Laboratories L.P. | Twyneo | $36 | 2 payments
|
| Pfizer | Eucrisa | $34 | 2 payments
|
| Dermavant Sciences | Vtama | $20 | 1 payment
|
| EPI Health | Cloderm | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $17 | 1 payment
|
| Boston Scientific | General - Pain Management | $16 | 1 payment
|
2021: $781
| AbbVie | Skyrizi | $306 | 20 payments
|
| Almirall | Seysara | $79 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $77 | 4 payments
|
| Sun Pharmaceutical Industries | Ilumya | $65 | 3 payments
|
| Janssen Biotech | Remicade | $54 | 3 payments
|
| Incyte | Opzelura | $38 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $37 | 2 payments
|
| Genzyme | Dupixent | $33 | 2 payments
|
| Galderma Laboratories L.P. | Oracea | $31 | 2 payments
|
| Lilly USA | Taltz | $22 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $20 | 1 payment
|
| Pfizer | Eucrisa | $18 | 1 payment
|
Professional record
- NPI
- 1477067239
- Licence
- CA 62769, CO PA.0005175, CT 5030California A62769: CancelledColorado PA.5175: Expired
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, surgical (363AS0400X); Physician assistant (363A00000X)
- Mailing address
- 761 Main Ave Ste 102, Norwalk, CT, 06851
- NPI first listed
- 2017-11-30
- NPI last updated
- 2023-06-29
- NPI record certified
- 2023-06-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 501 S Shore Ctr W Ste 103a, Alameda, CA, 94501 · 5420 Arapahoe Ave Ste A, Boulder, CO, 80303 · 1610 Prairie Center Pkwy Ste 2230, Brighton, CO, 80601 · 1140 W South Boulder Rd Ste 202, Lafayette, CO, 80026 · 2001 Union St Ste 520, San Francisco, CA, 94123 · 2420 Samaritan Dr, San Jose, CA, 95124